CLINICAL TRIALS PROFILE FOR FLUDARABINE PHOSPHATE

All Clinical Trials for FLUDARABINE PHOSPHATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00001586 ↗	Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): DNA Microarray Gene Expression Analysis	Completed	National Cancer Institute (NCI)	Phase 2	1997-09-01	Background: - Combined therapy with rituximab and fludarabine is the treatment of choice for advanced stage chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). - A new technology called deoxyribonucleic acid (DNA) microarray can be used to gain knowledge about the genetic basis of CLL/SLL. - Genetic studies of CLL/SLL may improve our understanding of what happens in the disease, help determine which patients are most likely to respond to treatment with fludarabine and rituximab, and identify new treatments. Objectives: -To gain further knowledge about CLL/SLL and the role of rituximab and fludarabine in treating the disease. Eligibility: -Patients 18 years of age and older with low, intermediate or high-risk CLL/SLL. Design: - Patients with low-risk CLL/SLL do not receive treatment, but are followed every 3 to 6 months and donate cells (through apheresis) or lymph nodes, or both, for research purposes. - Patients with intermediate or high-risk CLL/SLL receive standard treatment with rituximab and fludarabine for six 28-day treatment cycles. Rituximab is given on day 1 and fludarabine is given on days 1-5. (For the first cycle only, fludarabine treatment starts on day 2. This delay permits blood sampling on day 1 for the effect of rituximab on white blood cells.) - Laboratory tests and imaging studies are done periodically to monitor drug side effects and the response to treatment. Tests include bone marrow biopsy and aspiration, blood tests and x-rays, including positron emission tomography (PET) and computed tomography (CT) scans.
NCT00002779 ↗	Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma	Completed	National Cancer Institute (NCI)	Phase 2	1998-02-01	RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating patients who have relapsed low-grade non-Hodgkin's lymphoma.
NCT00002779 ↗	Fludarabine Plus Octreotide in Treating Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma	Completed	Alliance for Clinical Trials in Oncology	Phase 2	1998-02-01	RATIONALE: Drugs used in chemotherapy and hormone therapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of fludarabine plus octreotide in treating patients who have relapsed low-grade non-Hodgkin's lymphoma.
NCT00002798 ↗	Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 3	1996-08-01	Randomized phase III trial to compare the effectiveness of different chemotherapy regimens with or without bone marrow transplantation in treating children who have acute myelogenous leukemia or myelodysplastic syndrome. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. It is not yet known which treatment regimen is more effective for acute myelogenous leukemia or myelodysplastic syndrome
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833 ↗	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002838 ↗	Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	1995-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy and kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combination chemotherapy plus peripheral stem cell transplantation in treating patients with refractory chronic lymphocytic leukemia.

Clinical Trial Conditions for FLUDARABINE PHOSPHATE

Condition Name

Condition Name for FLUDARABINE PHOSPHATE
Intervention	Trials
Leukemia	171
Lymphoma	103
Myelodysplastic Syndromes	79
Myelodysplastic Syndrome	41

Condition MeSH

Condition MeSH for FLUDARABINE PHOSPHATE
Intervention	Trials
Leukemia	315
Myelodysplastic Syndromes	179
Preleukemia	172
Lymphoma	166

Clinical Trial Locations for FLUDARABINE PHOSPHATE

Trials by Country

Trials by Country for FLUDARABINE PHOSPHATE
Location	Trials
Canada	54
United Kingdom	33
Italy	32
Australia	25
Japan	21

Trials by US State

Trials by US State for FLUDARABINE PHOSPHATE
Location	Trials
Texas	131
Washington	105
California	82
New York	58
Maryland	54

Clinical Trial Progress for FLUDARABINE PHOSPHATE

Clinical Trial Phase

Clinical Trial Phase for FLUDARABINE PHOSPHATE
Clinical Trial Phase	Trials
PHASE2	3
PHASE1	9
Phase 4	2

Clinical Trial Status

Clinical Trial Status for FLUDARABINE PHOSPHATE
Clinical Trial Phase	Trials
Completed	249
Terminated	74
Recruiting	68

Clinical Trial Sponsors for FLUDARABINE PHOSPHATE

Sponsor Name

Sponsor Name for FLUDARABINE PHOSPHATE
Sponsor	Trials
National Cancer Institute (NCI)	292
M.D. Anderson Cancer Center	109
Fred Hutchinson Cancer Research Center	87

Sponsor Type

Sponsor Type for FLUDARABINE PHOSPHATE
Sponsor	Trials
Other	510
NIH	337
Industry	96

Fludarabine Phosphate: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is fludarabine phosphate’s clinical development status?

Fludarabine phosphate is an established oncology agent used in multiple hematologic malignancies. Its development is largely in the form of label maintenance, optimization of combination regimens, and trial activity around re-use in new settings rather than discovery-stage programs. Publicly disclosed trial activity is concentrated in the United States and Europe, with recurring endpoints tied to response rate, progression-free survival, overall survival, and toxicity.

Trial activity pattern (what is typically being studied)

Across interventional studies and regimen-combination work, fludarabine phosphate is used as:

• Conditioning or lymphodepleting chemotherapy backbone (commonly in transplant-adjacent or cellular therapy-adjacent protocols).
• Combination chemotherapy component in relapsed/refractory and treatment-naive hematologic cancers (notably lymphoid malignancies).
• Regimen optimization focused on safety (myelosuppression, infections), pharmacodynamic response, and feasibility in specific patient subgroups.

Clinical outcomes focus in recent trial disclosures

Trial disclosures that recur across this class of studies generally emphasize:

• Hematologic response (complete/partial response rates)
• Durability (progression-free survival)
• Survival (overall survival)
• Tolerability (grade 3/4 cytopenias, infection burden, transplant-related complications)

Practical read-across for pipeline monitoring

For fludarabine phosphate specifically, the “update” that matters commercially is whether new protocols expand use in earlier lines, broaden the transplant/cellular therapy addressable population, or materially shift standard-of-care through comparative data. Trial activity is most commercially relevant where it:

• Demonstrates a clear efficacy edge versus comparator conditioning or chemotherapy backbones
• Shows lower toxicity without sacrificing response
• Establishes repeatable eligibility for older/comorbid patients

Evidence base used for trial status and market context is drawn from public trial registry records and established prescribing/market references [1-3].

---

Where is the market today, and which end markets drive demand?

Fludarabine phosphate demand is driven by oncology care where lymphoid malignancies and transplant-conditioning regimens overlap. Commercial demand typically concentrates in:

• Hematologic oncology (relapsed/refractory and progressive lymphoid malignancies)
• Transplant conditioning and regimen frameworks where fludarabine is a standard component
• Hospital-based administration channels (oncology centers and transplant programs)

Market mechanics that shape near-term volume

Fludarabine’s commercial footprint is influenced by:

1. Inventory-driven hospital purchasing and regimen scheduling (short order cycle, batch stability requirements).
2. Formulation and availability (critical in conditioning regimens).
3. Pricing pressure from generics/biosimilars ecosystem and tendering behavior in EU markets.

Competitive landscape (what matters)

Because fludarabine phosphate is an established, long-used agent, the competitive set is dominated by:

• Originator and generic manufacturers
• Local supply breadth across US wholesalers and EU hospital formularies
• WAC-to-net pricing dynamics shaped by tenders and reimbursement

Market participants generally track the following commercial KPIs:

• Total units shipped to major oncology and transplant accounts
• Channel inventory levels and procurement timing
• Net price erosion versus list price for generic entrants
• Shortage events or supply interruptions that can temporarily shift procurement patterns

Sources reflect established product and trial registries, plus market reporting frameworks used for anticancer small-molecule demand surveillance [1-3].

---

What do clinical outcomes and regimen use imply for future demand?

The main demand lever is whether fludarabine phosphate continues to be selected as a standard backbone in:

• Conditioning regimens
• Combination chemotherapy standards
• Protocols that expand eligibility for lymphoid malignancies and transplant/cellular therapy workflows

Key adoption drivers

Fludarabine tends to maintain share when it:

• Has clinical protocol inclusion in widely used conditioning schemas
• Supports combination regimens that demonstrate acceptable risk-benefit
• Remains reliably available in supply chains with stable formulation access

Key headwinds

Demand can contract where:

• Protocols shift to alternative fludarabine-free or fludarabine-minimized backbones
• Toxicity profiles or logistics push centers toward different conditioning regimens
• Cost-driven procurement favors lower-cost alternatives with equivalent performance data

---

What is the market projection for fludarabine phosphate?

A defensible projection for fludarabine phosphate must rest on two pillars: (1) stable clinical adoption in conditioning/lymphoid oncology pathways, and (2) pricing and volume effects from generic competition. Publicly available market databases that enumerate total addressable revenue for fludarabine are not uniformly aligned on assay basis (drug substance vs packaged units), which makes projections highly sensitive to the underlying market model.

Given fludarabine phosphate’s mature status, projections typically show:

• Flat-to-low single-digit value growth driven by volume stability in core uses
• Net revenue pressure due to generic penetration and tender-based pricing

Projection framing used for mature oncology injectables

For mature oncology small molecules used in hospital settings, standard projection models assume:

• Volume changes modestly with patient population and protocol adoption
• Revenue is more sensitive to price erosion than to volume growth
• Growth events occur through guideline expansion or new regimen uptake rather than new molecular approvals

Accordingly, a base-case market outlook for fludarabine phosphate is:

• Volume: stable to modest growth
• Value (revenue): constrained by pricing pressure, with any uptake gains partially offset by net price declines

This projection is anchored to the mature and registry-confirmed role of fludarabine in ongoing trials and clinical protocols and to established oncology market monitoring approaches for older small-molecule therapies [1-3].

---

Clinical trials: where to watch for “commercially meaningful” updates

Commercially meaningful trial updates for fludarabine phosphate usually appear in these categories:

1) Conditioning regimen trials with hard comparative endpoints

• Comparative efficacy versus other lymphodepleting backbones
• Safety comparisons centered on infection and transplant-related morbidity

2) Combination chemotherapy protocols expanding earlier lines

• Demonstrated survival advantage or response durability that influences standard-of-care
• Evidence in broader patient eligibility categories

3) Patient subgroup studies affecting formulary inclusion

• Older patients and comorbidity feasibility
• Reduced toxicity strategies that improve deliverability

4) Studies tied to cellular therapy workflows

• Lymphodepletion protocols for adoptive immunotherapies
• Timing, dosing schedules, and outcome correlations

The practical monitoring approach is to prioritize registries that publish updated results, not just recruitment changes. Trial registry records provide the update cadence and endpoint metadata used by market teams to map activity to commercial impact [1].

---

What is the investment and R&D relevance of fludarabine phosphate now?

Fludarabine phosphate is not a typical “platform” drug with active brand-new discovery programs. The investment relevance is mainly:

• Supply chain and manufacturing resilience
• Formulation continuity and regulatory maintenance
• Protocol-driven demand durability

For R&D, the highest-value activities around an established agent are usually:

• Comparative regimen work that changes clinical practice
• New combination identification using established dosing tolerability data
• Optimization of administration schedules for hospitals

---

Key Takeaways

• Clinical activity is ongoing but mature: fludarabine phosphate is repeatedly used as a backbone in oncology and transplant-adjacent protocols rather than as a novel discovery-stage compound [1-3].
• Market demand is protocol-driven: volume is anchored by hematologic oncology and conditioning regimen inclusion in standard care pathways.
• Projection points to value pressure: generic and tender dynamics likely cap revenue growth even if protocol use stays stable.
• Commercially meaningful updates come from comparative outcomes: trials that change standard-of-care or expand eligibility have the highest impact on future demand.

---

FAQs

1) Is fludarabine phosphate still enrolling patients in clinical trials?

Yes. Public trial registries show ongoing interventional studies and regimen work that continue to use fludarabine phosphate as part of hematologic oncology and conditioning frameworks [1].

2) What endpoints matter most for market impact?

Response rate, progression-free survival, overall survival, and serious toxicity (particularly infection and cytopenias) are the endpoints most likely to drive protocol adoption [1-3].

3) What most influences fludarabine phosphate revenue: volume or price?

Price. In mature oncology small molecules with generic penetration, net revenue usually responds more to price erosion and tendering than to modest volume shifts.

4) Which clinical areas drive fludarabine phosphate utilization?

Hematologic malignancies and conditioning regimen use tied to transplant or cellular therapy workflows [2,3].

5) What trial updates should formulary teams prioritize?

Comparative trials showing improved efficacy or reduced clinically meaningful toxicity that would plausibly lead to changes in guideline inclusion or hospital protocol choice [1].

---

References

[1] ClinicalTrials.gov. (n.d.). Search results and record updates for fludarabine phosphate (accessed 2026-04-28).
[2] U.S. Food and Drug Administration. (n.d.). Fludarabine phosphate prescribing information and related regulatory materials (accessed 2026-04-28).
[3] European Medicines Agency. (n.d.). Public assessment reports and product information relevant to fludarabine phosphate (accessed 2026-04-28).